Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acyl-coenzyme A synthetase ACSM6, mitochondrial (ACSM6), is an enzyme localized in the mitochondria that catalyzes the ATP-dependent conversion of medium-chain fatty acids (typically C4–C12) into their respective acyl-CoA thioesters[1][2][4][5]. This activation reaction is critical for fatty acid metabolism, serving as the entry step for mitochondrial β-oxidation (energy production) and lipid biosynthetic pathways. The enzyme is predicted to have fatty acid ligase and fatty-acyl-CoA synthase activities. ACSM6 is a member of the acyl-CoA synthetase family, is primarily expressed in various tissues, and may influence metabolic homeostasis, as changes in its activity have been correlated with altered mitochondrial respiration, especially in aging tissues[1][2]. Although dysfunction of ACSM6 or related enzymes may contribute to metabolic disorders, there is currently no evidence of approved drugs or biomarkers specifically targeting ACSM6[2][4][5].
Catalyzes ATP-dependent conversion of medium-chain fatty acids into acyl-CoA thioesters, facilitating their channeling into mitochondrial β-oxidation and lipid biosynthesis[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acyl-coenzyme A synthetase ACSM6, mitochondrial (ACSM6).